Skip to main content
main-content

medwireNews@ESMO2016

medwireNews@ESMO2016

18-10-2016 | Gynaecological cancer | News | Article

Editor's pick

Niraparib maintenance ‘warranted’ for platinum-sensitive recurrent ovarian cancer

ENGOT-OV16/NOVA trial results support the use of maintenance treatment with niraparib for platinum-sensitive recurrent ovarian cancer, in both patients with and without a germline BRCA mutation.

Source:

N Engl J Med 2016; Advance online publication;  ESMO 2016; Copenhagen, Denmark

More ESMO 2016 coverage

09-11-2016 | Non-small-cell lung cancer | News | Article

Ceritinib outperforms chemotherapy in pretreated ALK-positive NSCLC

The ASCEND-5 trial results establish ceritinib as a valid option for pretreated non-small-cell lung cancer patients harboring anaplastic lymphoma kinase translocations.

07-11-2016 | Non-small-cell lung cancer | News | Article

Atezolizumab prolongs advanced NSCLC overall survival

The programmed death-ligand 1 directed antibody atezolizumab confers an overall survival advantage relative to docetaxel in previously treated patients with locally advanced or metastatic non-small-cell lung cancer, indicate phase III trial findings.

03-11-2016 | Melanoma | News | Article

Melanoma survival extension with adjuvant ipilimumab comes at toxicity cost

Updated phase III trial results show that ipilimumab treatment improves overall survival and distant metastasis-free survival in stage III melanoma patients who have undergone complete resection, but with increased toxicity relative to placebo.

image credits